semaglutide kidney disease Long-term outcomes of in obesity and cardiovascular in the SELECT trial Diabetes Distilled: Keeping kidneys FLOWing

10 / 2026 Zealand Pharma announces Boehringer Ingelheim's novel glucagon/GLP-1 dual agonist survodutide achieved significant weight loss of 16.6% delivering meaningful metabolic improvement in people living with obesity or overweight in Phase 3 trial In SYNCHRONIZE-1, participants lost up to an average of 39.2 lb (17.8 kg) from baseline after 76 weeks of treatment with survodutide, a glucagon/GLP-1 receptor dual agonist1 The trial met both weight loss primary endpoints and its key secondary endpoint evaluating waist circumference, a predictor of cardiometabolic risk, together demonstrating survodutide's potential to broadly improve metabolic health1 In addition to these positive results, Boehringer is advancing its broad metabolic health R&D program, exploring multiple pharmaceutical approaches to weight management including oral treatments

As we age, our glutathione levels naturally decline, contributing to an uneven skin tone and the appearance of age spots or hyperpigmentation

Bttcher, C

They were instructed to return after at least 7 days for a third visit, fasting as before

Antioxidant Facials and Peels We combine topical Vitamin C serums, mild peels, and hydrating antioxidant masks to restore radiance and even tone